IMO the pooled safety data to me means there is po
Post# of 152710
indications starting out in clinical trials may be able to skip phase 1, or move along much faster.
for other indications with some form of clinical trial having been completed, if they show a signal that patients improve in some way better than standard of care, the next step is phase 3.
I'm unsure if this pooled safety data may open the possibility for trials to use leronlimab as an early line of treatment, rather than start with salvage patients. I think this possibility may come to be sooner than I had earlier expected if the oncology MOA is stunning.

